Clinical trial
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
NCT02505334 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 21, 2015
- Completion date
- November 9, 2017
- Enrollment
- 635 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes, diabetes mellitus, type 2